Predictive Factors of Ranibizumab Treatment in Macular Edema With CRVO
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Recent studies have shown that intravitreal injection of anti-VEGF agent, Lucentis
(Ranibizumab) is effective for macular edema associated with central retinal vein occlusion
(CRVO). However, there is little information on whether there are any predictive factors of
treatment outcome after this treatment. We plan to perform comprehensive functional and
imaging tests to determine significant predictive factors.